Dr. Stéphanie McArdle leads the development and assessment of peptide-derived tumour associated antigen vaccines, including a novel and patented prostatic acid phosphatase-derived vaccine (PAP), and a HAGE and NY-ESO1 based vaccines. In addition, two other vaccines are currently being assessed in collaboration with Scancell Ltd for the treatment of GBM. Moreover, it is known that the functionality of the immune system declines with age ('immune senescence') and that it is also influenced by nutritional and stress status. Given that the gut microflora is altered in individuals over 60 years old and that 70% of our immune system is located in the gut mucosa, it is essential that potential immunotherapeutic strategies are evaluated in pre-clinical models that more closely represent the clinical situation. The new vaccines comprised of PAP peptide delivered prophylactically or therapeutically will be assessed in aged animals with / without supplementation of their diet with a symbiotic which promotes beneficial gut bacteria. It will thereby determine the synergistic interaction between cancer vaccination and controlled modification of the microbiome in a more relevant mouse model. Given the important influence of food, stress/emotional status, exercise, and sleep on the immune system in health and in disease, Stéphanie is organising for the second time “Health and WellBeing Day" scheduled for April 12th 2018 at NTU Clifton. Stéphanie has established many collaborations with national and international laboratories and overseen an International project involving nine laboratories which was then presented at the European Society of cancer and immunotherapy (ESCII) conference held in Athens, Oct. 2008. Stéphanie has also organised two ELISPOT workshops in collaboration with Cellular Technology Ltd (CTLdt) and PIVAC 12 conference which were all great successes. Stéphanie is also an active member of the SGI/UK, a Buddhist organisation for world-wide peace.